The rhophylac market research report is one of a series of new reports that provides rhophylac market statistics, including the rhophylac industry global market size, regional shares, competitors with the rhophylac market share, detailed rhophylac market segments, market trends, and opportunities, and any further data you may need to thrive in the rhophylac industry. This rhophylac market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to growing awareness of blood safety, government and health organization initiatives, improved healthcare infrastructure, advancements in immunoglobulin delivery, and rising transplantation procedures. Major trends in the forecast period include technological advancements in blood products, adoption of automated blood group typing technologies, technological advancements in drug formulation, and enhanced diagnosis and detection techniques.
The growing awareness of blood safety is expected to significantly drive the growth of the rhophylac market in the future. Blood safety involves practices aimed at preventing contamination and the transmission of infections, ensuring that blood and blood products are safe through measures such as donor screening, disease testing, and proper storage and handling. Increased public health campaigns, advancements in blood screening technology, stricter regulations, and global health crises have all contributed to heightened awareness of blood safety. Additionally, the rising incidents of bloodborne diseases and improved medical training have further emphasized the need for better blood management. Rhophylac plays a role in raising awareness by preventing Rh incompatibility in pregnant women, thereby reducing the risk of hemolytic disease of the newborn. For instance, in December 2023, the UK Health Security Agency reported that blood donations continued to increase, with 1.8 million donations made in 2022. Moreover, in August 2023, the Royal College of Pathologists highlighted that blood transfusions are among the most commonly performed procedures for hospitalized patients, with nearly 2 million blood components issued annually in England, underscoring the importance of safe blood management. This growing focus on blood safety is driving the demand for rhophylac.
The rise in organ transplants is also expected to contribute to the growth of the rhophylac market. Organ transplants involve replacing a damaged or failing organ in a patient with a healthy one from a donor, often saving or significantly improving the patient’s life. The increasing number of organ transplants is due to advancements in medical technology, better surgical techniques, improved post-transplant care, and a greater awareness of organ donation. Rhophylac is used during organ transplants to prevent immune rejection and alloimmunization by offering passive immunization with Rh immunoglobulin, which reduces the risk of sensitization to foreign antigens. In 2022, according to the United Network for Organ Sharing, the United States saw 42,887 organ transplants, marking a 3.7% increase from the previous year. This rise in organ transplant procedures is expected to further boost the demand for rhophylac.
The growing healthcare expenditure is another key factor driving the growth of the rhophylac market. Healthcare expenditure refers to the total amount spent on healthcare services and products within a specific timeframe. The increase in healthcare spending is driven by factors such as aging populations, advancements in medical technology, and an increasing demand for healthcare services. Rhophylac helps reduce healthcare costs by preventing complications related to Rh incompatibility in pregnancy, thereby preventing the need for costly treatments associated with hemolytic disease of the newborn. In 2023, Austria's healthcare expenditure reached $56.47 billion (€52.28 billion), representing 10.9% of the nation's GDP, according to Statistics Austria. This marked a 4.8% increase from the previous year, reflecting a broader trend of rising healthcare costs, which in turn supports the growing demand for rhophylac.
The countries covered in the rhophylac market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Rhophylac is a human anti-D immunoglobulin used to prevent Rh immunization in Rh-negative individuals who have been exposed to Rh-positive red blood cells. It is commonly administered during pregnancy, after childbirth, or following blood transfusions to prevent complications such as hemolytic disease of the newborn.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Rhophylac include the suppression of Rh isoimmunization, management of incompatible transfusions, and treatment of immune thrombocytopenic purpura (ITP). Suppressing Rh isoimmunization involves administering Rh immunoglobulin (RhIg) to an Rh-negative mother to prevent her immune system from producing antibodies against Rh-positive fetal blood cells, thus reducing the risk of complications in subsequent pregnancies. Rhophylac is administered via intravenous (IV) or intramuscular (IM) injections and is distributed through various channels, including hospitals, clinics, and pharmacies. It is used by a wide range of patients, including pediatric, adult, and geriatric populations.
The rhophylac market consists of sales of injections, vials, pre-filled syringes, rh immunoglobulin products, and companion products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growing awareness of blood safety, government and health organization initiatives, improved healthcare infrastructure, advancements in immunoglobulin delivery, and rising transplantation procedures. Major trends in the forecast period include technological advancements in blood products, adoption of automated blood group typing technologies, technological advancements in drug formulation, and enhanced diagnosis and detection techniques.
The growing awareness of blood safety is expected to significantly drive the growth of the rhophylac market in the future. Blood safety involves practices aimed at preventing contamination and the transmission of infections, ensuring that blood and blood products are safe through measures such as donor screening, disease testing, and proper storage and handling. Increased public health campaigns, advancements in blood screening technology, stricter regulations, and global health crises have all contributed to heightened awareness of blood safety. Additionally, the rising incidents of bloodborne diseases and improved medical training have further emphasized the need for better blood management. Rhophylac plays a role in raising awareness by preventing Rh incompatibility in pregnant women, thereby reducing the risk of hemolytic disease of the newborn. For instance, in December 2023, the UK Health Security Agency reported that blood donations continued to increase, with 1.8 million donations made in 2022. Moreover, in August 2023, the Royal College of Pathologists highlighted that blood transfusions are among the most commonly performed procedures for hospitalized patients, with nearly 2 million blood components issued annually in England, underscoring the importance of safe blood management. This growing focus on blood safety is driving the demand for rhophylac.
The rise in organ transplants is also expected to contribute to the growth of the rhophylac market. Organ transplants involve replacing a damaged or failing organ in a patient with a healthy one from a donor, often saving or significantly improving the patient’s life. The increasing number of organ transplants is due to advancements in medical technology, better surgical techniques, improved post-transplant care, and a greater awareness of organ donation. Rhophylac is used during organ transplants to prevent immune rejection and alloimmunization by offering passive immunization with Rh immunoglobulin, which reduces the risk of sensitization to foreign antigens. In 2022, according to the United Network for Organ Sharing, the United States saw 42,887 organ transplants, marking a 3.7% increase from the previous year. This rise in organ transplant procedures is expected to further boost the demand for rhophylac.
The growing healthcare expenditure is another key factor driving the growth of the rhophylac market. Healthcare expenditure refers to the total amount spent on healthcare services and products within a specific timeframe. The increase in healthcare spending is driven by factors such as aging populations, advancements in medical technology, and an increasing demand for healthcare services. Rhophylac helps reduce healthcare costs by preventing complications related to Rh incompatibility in pregnancy, thereby preventing the need for costly treatments associated with hemolytic disease of the newborn. In 2023, Austria's healthcare expenditure reached $56.47 billion (€52.28 billion), representing 10.9% of the nation's GDP, according to Statistics Austria. This marked a 4.8% increase from the previous year, reflecting a broader trend of rising healthcare costs, which in turn supports the growing demand for rhophylac.
The key company operating in the rhophylac market is CSL Behring AG
North America was the largest region in the rhophylac market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rhophylac report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the rhophylac market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Rhophylac is a human anti-D immunoglobulin used to prevent Rh immunization in Rh-negative individuals who have been exposed to Rh-positive red blood cells. It is commonly administered during pregnancy, after childbirth, or following blood transfusions to prevent complications such as hemolytic disease of the newborn.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Rhophylac include the suppression of Rh isoimmunization, management of incompatible transfusions, and treatment of immune thrombocytopenic purpura (ITP). Suppressing Rh isoimmunization involves administering Rh immunoglobulin (RhIg) to an Rh-negative mother to prevent her immune system from producing antibodies against Rh-positive fetal blood cells, thus reducing the risk of complications in subsequent pregnancies. Rhophylac is administered via intravenous (IV) or intramuscular (IM) injections and is distributed through various channels, including hospitals, clinics, and pharmacies. It is used by a wide range of patients, including pediatric, adult, and geriatric populations.
The rhophylac market consists of sales of injections, vials, pre-filled syringes, rh immunoglobulin products, and companion products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Rhophylac Market Characteristics4. Rhophylac Market Trends And Strategies5. Rhophylac Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Rhophylac Pricing Analysis & Forecasts30. Global Rhophylac Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Rhophylac Market32. Recent Developments In The Rhophylac Market
3. Rhophylac Market Biologic Drug Characteristics
6. Global Rhophylac Growth Analysis And Strategic Analysis Framework
8. Rhophylac Market Segmentation
9. Global Rhophylac Epidemiology Of Clinical Indications
10. Rhophylac Market Regional And Country Analysis
11. Asia-Pacific Rhophylac Market
12. China Rhophylac Market
13. India Rhophylac Market
14. Japan Rhophylac Market
15. Australia Rhophylac Market
16. South Korea Rhophylac Market
17. Western Europe Rhophylac Market
18. UK Rhophylac Market
19. Germany Rhophylac Market
20. France Rhophylac Market
21. Eastern Europe Rhophylac Market
22. North America Rhophylac Market
23. USA Rhophylac Market
24. Canada Rhophylac Market
25. South America Rhophylac Market
26. Middle East Rhophylac Market
27. Africa Rhophylac Market
28. Rhophylac Market Competitive Landscape And Company Profiles
29. Global Rhophylac Market Pipeline Analysis
33. Rhophylac Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Rhophylac Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on rhophylac market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for rhophylac ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rhophylac market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Suppression Of Rh Isoimmunization; Incompatible Transfusions; Immune Thrombocytopenic Purpura (ITP)2) By Administration: Intravenous (IV); Intramuscular (IM)
3) By Distribution Channel: Hospitals; Clinics; Pharmacies
4) By End User: Pediatric; Adult; Geriatric
Key Companies Profiled: CSL Behring AG
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- CSL Behring AG